EA011953B1 - Pdx1-экспрессирующая энтодерма - Google Patents
Pdx1-экспрессирующая энтодерма Download PDFInfo
- Publication number
- EA011953B1 EA011953B1 EA200601995A EA200601995A EA011953B1 EA 011953 B1 EA011953 B1 EA 011953B1 EA 200601995 A EA200601995 A EA 200601995A EA 200601995 A EA200601995 A EA 200601995A EA 011953 B1 EA011953 B1 EA 011953B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cells
- endoderm
- positive
- cell
- expression
- Prior art date
Links
- 210000001900 endoderm Anatomy 0.000 title claims description 463
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 title abstract 5
- 210000004027 cell Anatomy 0.000 claims abstract description 793
- 210000004039 endoderm cell Anatomy 0.000 claims abstract description 324
- 238000004113 cell culture Methods 0.000 claims abstract description 157
- 108090000623 proteins and genes Proteins 0.000 claims description 234
- 239000003550 marker Substances 0.000 claims description 140
- 210000000936 intestine Anatomy 0.000 claims description 127
- 230000000968 intestinal effect Effects 0.000 claims description 83
- 210000005260 human cell Anatomy 0.000 claims description 63
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 54
- 230000009278 visceral effect Effects 0.000 claims description 42
- 150000004492 retinoid derivatives Chemical class 0.000 claims description 35
- 230000001936 parietal effect Effects 0.000 claims description 28
- 210000001519 tissue Anatomy 0.000 claims description 26
- 210000001161 mammalian embryo Anatomy 0.000 claims description 17
- 210000000056 organ Anatomy 0.000 claims description 17
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 16
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 16
- 210000002894 multi-fate stem cell Anatomy 0.000 claims description 14
- 210000002569 neuron Anatomy 0.000 claims description 14
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 13
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 10
- 230000002710 gonadal effect Effects 0.000 claims description 6
- 230000002183 duodenal effect Effects 0.000 claims description 4
- 210000000472 morula Anatomy 0.000 claims description 4
- 101150051519 C6 gene Proteins 0.000 claims description 3
- 101150016059 HOXA13 gene Proteins 0.000 claims description 3
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 315
- 230000004069 differentiation Effects 0.000 abstract description 271
- 210000002438 upper gastrointestinal tract Anatomy 0.000 abstract description 2
- 102100035459 Pyruvate dehydrogenase protein X component, mitochondrial Human genes 0.000 abstract 4
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 description 361
- 108010023082 activin A Proteins 0.000 description 123
- 210000002966 serum Anatomy 0.000 description 118
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 109
- 229930002330 retinoic acid Natural products 0.000 description 109
- 229960001727 tretinoin Drugs 0.000 description 109
- 239000002609 medium Substances 0.000 description 75
- 230000001605 fetal effect Effects 0.000 description 55
- 102000004169 proteins and genes Human genes 0.000 description 50
- 238000003753 real-time PCR Methods 0.000 description 47
- 239000003636 conditioned culture medium Substances 0.000 description 43
- 108010059616 Activins Proteins 0.000 description 42
- 102000005606 Activins Human genes 0.000 description 42
- 239000000488 activin Substances 0.000 description 42
- 238000007792 addition Methods 0.000 description 42
- 108010079274 Thrombomodulin Proteins 0.000 description 38
- 239000000203 mixture Substances 0.000 description 38
- 230000015572 biosynthetic process Effects 0.000 description 37
- 102000012607 Thrombomodulin Human genes 0.000 description 35
- 239000003102 growth factor Substances 0.000 description 32
- 108010023079 activin B Proteins 0.000 description 30
- 210000003716 mesoderm Anatomy 0.000 description 30
- 238000004458 analytical method Methods 0.000 description 28
- 238000002955 isolation Methods 0.000 description 27
- 238000002474 experimental method Methods 0.000 description 25
- 210000002950 fibroblast Anatomy 0.000 description 23
- 238000011161 development Methods 0.000 description 22
- 230000018109 developmental process Effects 0.000 description 22
- 210000003981 ectoderm Anatomy 0.000 description 22
- 230000007423 decrease Effects 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 230000004936 stimulating effect Effects 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 17
- UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 230000000638 stimulation Effects 0.000 description 14
- 101001099372 Homo sapiens Peroxisome biogenesis factor 1 Proteins 0.000 description 13
- 102100038881 Peroxisome biogenesis factor 1 Human genes 0.000 description 13
- 210000000496 pancreas Anatomy 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- 230000007045 gastrulation Effects 0.000 description 12
- 210000004153 islets of langerhan Anatomy 0.000 description 12
- 239000010410 layer Substances 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 150000003384 small molecules Chemical group 0.000 description 12
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 11
- 108700008625 Reporter Genes Proteins 0.000 description 11
- 230000034127 bone morphogenesis Effects 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 10
- 239000012737 fresh medium Substances 0.000 description 10
- 230000003053 immunization Effects 0.000 description 10
- 238000002649 immunization Methods 0.000 description 10
- 238000001262 western blot Methods 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- 101100009781 Danio rerio dmbx1a gene Proteins 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 101150105372 POX1 gene Proteins 0.000 description 8
- 101100194320 Zea mays PER1 gene Proteins 0.000 description 8
- 238000010306 acid treatment Methods 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 239000006143 cell culture medium Substances 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 238000001000 micrograph Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 210000000130 stem cell Anatomy 0.000 description 8
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 210000004940 nucleus Anatomy 0.000 description 7
- 210000001778 pluripotent stem cell Anatomy 0.000 description 7
- 230000008054 signal transmission Effects 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 102000019034 Chemokines Human genes 0.000 description 6
- 108010012236 Chemokines Proteins 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 238000002659 cell therapy Methods 0.000 description 6
- 230000001143 conditioned effect Effects 0.000 description 6
- 230000003750 conditioning effect Effects 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 210000002257 embryonic structure Anatomy 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 238000010606 normalization Methods 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 102000009410 Chemokine receptor Human genes 0.000 description 5
- 108050000299 Chemokine receptor Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 241000252212 Danio rerio Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 210000001654 germ layer Anatomy 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 210000001704 mesoblast Anatomy 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 101100004408 Arabidopsis thaliana BIG gene Proteins 0.000 description 3
- 102100039486 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 4 Human genes 0.000 description 3
- 101100485279 Drosophila melanogaster emb gene Proteins 0.000 description 3
- 102100029095 Exportin-1 Human genes 0.000 description 3
- 101150025110 HOXC6 gene Proteins 0.000 description 3
- 101000609775 Homo sapiens Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 4 Proteins 0.000 description 3
- 241000208202 Linaceae Species 0.000 description 3
- 235000004431 Linum usitatissimum Nutrition 0.000 description 3
- 101100520126 Oryza sativa subsp. japonica PIN1A gene Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 101100485284 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CRM1 gene Proteins 0.000 description 3
- 101100194313 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) REH1 gene Proteins 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 101150094313 XPO1 gene Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000002459 blastocyst Anatomy 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 210000002242 embryoid body Anatomy 0.000 description 3
- 108700002148 exportin 1 Proteins 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000004720 fertilization Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 230000000984 immunochemical effect Effects 0.000 description 3
- 238000012760 immunocytochemical staining Methods 0.000 description 3
- 238000003365 immunocytochemistry Methods 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 239000006249 magnetic particle Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000011278 mitosis Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000005305 organ development Effects 0.000 description 3
- 238000003672 processing method Methods 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 238000004445 quantitative analysis Methods 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- 102100037839 Acidic mammalian chitinase Human genes 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 102000000905 Cadherin Human genes 0.000 description 2
- 108050007957 Cadherin Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 101000738085 Homo sapiens Acidic mammalian chitinase Proteins 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101150038023 PEX1 gene Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000006467 TATA-Box Binding Protein Human genes 0.000 description 2
- 108010044281 TATA-Box Binding Protein Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 229940095074 cyclic amp Drugs 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 210000001705 ectoderm cell Anatomy 0.000 description 2
- 210000003890 endocrine cell Anatomy 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002795 fluorescence method Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 210000001020 neural plate Anatomy 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 239000012130 whole-cell lysate Substances 0.000 description 2
- XOYSDPUJMJWCBH-VKHMYHEASA-N (3s)-3,5-diamino-5-oxopentanoic acid Chemical compound NC(=O)C[C@H](N)CC(O)=O XOYSDPUJMJWCBH-VKHMYHEASA-N 0.000 description 1
- VCGFSKNCUIRVDA-UHFFFAOYSA-N 1-[methyl(nitroso)amino]butyl acetate Chemical compound CCCC(OC(C)=O)N(C)N=O VCGFSKNCUIRVDA-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- 241001182632 Akko Species 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 101100366711 Arabidopsis thaliana SSL13 gene Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 102100026031 Beta-glucuronidase Human genes 0.000 description 1
- 102100028845 Biogenesis of lysosome-related organelles complex 1 subunit 2 Human genes 0.000 description 1
- 101710117545 C protein Proteins 0.000 description 1
- 101100131772 Caenorhabditis elegans mtss-1 gene Proteins 0.000 description 1
- 102100036807 Carboxylesterase 4A Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108010072210 Cyclophilin C Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 102100030012 Deoxyribonuclease-1 Human genes 0.000 description 1
- 101710206036 Deoxyribonuclease-1 Proteins 0.000 description 1
- 101001014194 Dictyostelium discoideum Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 102000004864 Fibroblast growth factor 10 Human genes 0.000 description 1
- 108090001047 Fibroblast growth factor 10 Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100040299 Guided entry of tail-anchored proteins factor 1 Human genes 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 102100030307 Homeobox protein Hox-A13 Human genes 0.000 description 1
- 102100039541 Homeobox protein Hox-A3 Human genes 0.000 description 1
- 102100022649 Homeobox protein Hox-A6 Human genes 0.000 description 1
- 102100022599 Homeobox protein Hox-C6 Human genes 0.000 description 1
- 102100037099 Homeobox protein MOX-1 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100437724 Homo sapiens BLOC1S2 gene Proteins 0.000 description 1
- 101000933465 Homo sapiens Beta-glucuronidase Proteins 0.000 description 1
- 101000851617 Homo sapiens Carboxylesterase 4A Proteins 0.000 description 1
- 101001038390 Homo sapiens Guided entry of tail-anchored proteins factor 1 Proteins 0.000 description 1
- 101001083162 Homo sapiens Homeobox protein Hox-A13 Proteins 0.000 description 1
- 101000962622 Homo sapiens Homeobox protein Hox-A3 Proteins 0.000 description 1
- 101001045083 Homo sapiens Homeobox protein Hox-A6 Proteins 0.000 description 1
- 101001045154 Homo sapiens Homeobox protein Hox-C6 Proteins 0.000 description 1
- 101000955035 Homo sapiens Homeobox protein MOX-1 Proteins 0.000 description 1
- 101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 1
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 1
- 101001108219 Homo sapiens NADPH oxidase 1 Proteins 0.000 description 1
- 101001098352 Homo sapiens OX-2 membrane glycoprotein Proteins 0.000 description 1
- 101000730368 Homo sapiens Phosducin Proteins 0.000 description 1
- 101000763314 Homo sapiens Thrombomodulin Proteins 0.000 description 1
- 101000648265 Homo sapiens Thymocyte selection-associated high mobility group box protein TOX Proteins 0.000 description 1
- 101000976622 Homo sapiens Zinc finger protein 42 homolog Proteins 0.000 description 1
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 1
- 108010066302 Keratin-19 Proteins 0.000 description 1
- 241000283891 Kobus Species 0.000 description 1
- 101000844802 Lacticaseibacillus rhamnosus Teichoic acid D-alanyltransferase Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100042271 Mus musculus Sema3b gene Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101100438536 Nicotiana plumbaginifolia CABC gene Proteins 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000009890 Osteonectin Human genes 0.000 description 1
- 108010077077 Osteonectin Proteins 0.000 description 1
- 101100366561 Panax ginseng SS11 gene Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100024968 Peptidyl-prolyl cis-trans isomerase C Human genes 0.000 description 1
- 102100032600 Phosducin Human genes 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101150021208 SIT2 gene Proteins 0.000 description 1
- 108091006299 SLC2A2 Proteins 0.000 description 1
- 208000004350 Strabismus Diseases 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 102100026966 Thrombomodulin Human genes 0.000 description 1
- 102100028788 Thymocyte selection-associated high mobility group box protein TOX Human genes 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
- 108010092867 Transforming Growth Factor beta Receptors Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 102100023550 Zinc finger protein 42 homolog Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000007801 affinity label Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000014107 chromosome localization Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000001953 common bile duct Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000001096 cystic duct Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000007646 directional migration Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- CWHBCTLVWOCMPQ-UHFFFAOYSA-L disodium;2-[(3,5-diiodo-4-oxidophenyl)-(3,5-diiodo-4-oxocyclohexa-2,5-dien-1-ylidene)methyl]benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C(C=1C=C(I)C([O-])=C(I)C=1)=C1C=C(I)C(=O)C(I)=C1 CWHBCTLVWOCMPQ-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 210000003158 enteroendocrine cell Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002907 exocrine cell Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000000646 extraembryonic cell Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 239000010520 ghee Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 102000051206 human THBD Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000012308 immunohistochemistry method Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940068935 insulin-like growth factor 2 Drugs 0.000 description 1
- 230000004608 intestinal differentiation Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000010311 mammalian development Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- 210000000276 neural tube Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 125000001474 phenylpropanoid group Chemical group 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- -1 retinoic acid (CA) Chemical class 0.000 description 1
- 125000002678 retinoid group Chemical group 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000020509 sex determination Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- ALPWRKFXEOAUDR-GKEJWYBXSA-M sodium;[(2r)-2,3-di(octadecanoyloxy)propyl] hydrogen phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)([O-])=O)OC(=O)CCCCCCCCCCCCCCCCC ALPWRKFXEOAUDR-GKEJWYBXSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
- 210000002023 somite Anatomy 0.000 description 1
- 230000023895 stem cell maintenance Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000003582 thrombocytopenic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000008189 vertebrate development Effects 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0679—Cells of the gastro-intestinal tract
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/99—Serum-free medium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56629304P | 2004-04-27 | 2004-04-27 | |
| US58656604P | 2004-07-09 | 2004-07-09 | |
| US58794204P | 2004-07-14 | 2004-07-14 | |
| US11/021,618 US7510876B2 (en) | 2003-12-23 | 2004-12-23 | Definitive endoderm |
| PCT/US2005/014239 WO2005116073A2 (en) | 2004-04-27 | 2005-04-26 | Pdx1 expressing endoderm |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200601995A1 EA200601995A1 (ru) | 2007-06-29 |
| EA011953B1 true EA011953B1 (ru) | 2009-06-30 |
Family
ID=45319532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200601995A EA011953B1 (ru) | 2004-04-27 | 2005-04-26 | Pdx1-экспрессирующая энтодерма |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1740612B1 (enExample) |
| JP (6) | JP4926946B2 (enExample) |
| KR (2) | KR101395516B1 (enExample) |
| CN (1) | CN103103158B (enExample) |
| AU (1) | AU2005247869B2 (enExample) |
| CA (1) | CA2564114C (enExample) |
| DK (2) | DK2377922T3 (enExample) |
| EA (1) | EA011953B1 (enExample) |
| ES (2) | ES2751095T3 (enExample) |
| IL (1) | IL178847A (enExample) |
| MX (1) | MXPA06012445A (enExample) |
| NZ (1) | NZ550605A (enExample) |
| SG (1) | SG152273A1 (enExample) |
| WO (1) | WO2005116073A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2668798C2 (ru) * | 2011-12-22 | 2018-10-02 | Янссен Байотек, Инк. | Способы in vitro пошаговой дифференцировки полюрипотентных клеток |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7625753B2 (en) | 2003-12-23 | 2009-12-01 | Cythera, Inc. | Expansion of definitive endoderm cells |
| US8647873B2 (en) | 2004-04-27 | 2014-02-11 | Viacyte, Inc. | PDX1 expressing endoderm |
| WO2007059007A2 (en) | 2005-11-14 | 2007-05-24 | Cythera, Inc. | Markers of definitive endoderm |
| US20050266554A1 (en) | 2004-04-27 | 2005-12-01 | D Amour Kevin A | PDX1 expressing endoderm |
| US7985585B2 (en) | 2004-07-09 | 2011-07-26 | Viacyte, Inc. | Preprimitive streak and mesendoderm cells |
| US7541185B2 (en) | 2003-12-23 | 2009-06-02 | Cythera, Inc. | Methods for identifying factors for differentiating definitive endoderm |
| KR101221302B1 (ko) | 2003-12-23 | 2013-01-11 | 비아싸이트, 인크. | 완전 내배엽 |
| AU2005272078B2 (en) * | 2004-07-09 | 2011-04-14 | Viacyte, Inc. | Methods for identifying factors for differentiating definitive endoderm |
| EP1791952A4 (en) | 2004-08-13 | 2008-06-11 | Univ Georgia Res Found | COMPOSITIONS AND METHODS OF SELF-RENEWAL AND DIFFERENTIATION IN HUMAN EMBRYONAL STEM CELLS |
| US8017395B2 (en) | 2004-12-17 | 2011-09-13 | Lifescan, Inc. | Seeding cells on porous supports |
| AU2005322007B2 (en) * | 2004-12-23 | 2011-06-30 | Viacyte, Inc. | Expansion of definitive endoderm cells |
| JP2008528038A (ja) * | 2005-01-31 | 2008-07-31 | エス セル インターナショナル ピーティーイー リミテッド | 胚性幹細胞の指示された分化及びその利用 |
| CN101282652B (zh) * | 2005-06-02 | 2013-09-11 | 亚利桑那董事会（代表亚利桑那大学） | 预血管化的装置及相关方法 |
| CA2613889A1 (en) | 2005-06-08 | 2006-12-14 | Centocor, Inc. | A cellular therapy for ocular degeneration |
| AU2012202481B2 (en) * | 2005-10-27 | 2015-07-02 | Viacyte, Inc. | PDX1-expressing dorsal and ventral foregut endoderm |
| EP3584311A1 (en) * | 2005-10-27 | 2019-12-25 | Viacyte, Inc. | Pdx-1 expressing dorsal and ventral foregut endoderm |
| EP1994141B1 (en) | 2006-02-23 | 2017-11-15 | ViaCyte, Inc. | Compositions and methods useful for culturing differentiable cells |
| CA2644468C (en) * | 2006-03-02 | 2022-02-01 | Cythera, Inc. | Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production |
| US7695965B2 (en) | 2006-03-02 | 2010-04-13 | Cythera, Inc. | Methods of producing pancreatic hormones |
| US11254916B2 (en) | 2006-03-02 | 2022-02-22 | Viacyte, Inc. | Methods of making and using PDX1-positive pancreatic endoderm cells |
| US8741643B2 (en) | 2006-04-28 | 2014-06-03 | Lifescan, Inc. | Differentiation of pluripotent stem cells to definitive endoderm lineage |
| EP2021462B1 (en) * | 2006-04-28 | 2019-01-09 | Lifescan, Inc. | Differentiation of human embryonic stem cells |
| US7989204B2 (en) | 2006-04-28 | 2011-08-02 | Viacyte, Inc. | Hepatocyte lineage cells |
| US9080145B2 (en) | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
| CA3114827C (en) | 2007-07-31 | 2023-09-05 | Lifescan, Inc. | Differentiation of human embryonic stem cells to pancreatic endocrine |
| US7695963B2 (en) | 2007-09-24 | 2010-04-13 | Cythera, Inc. | Methods for increasing definitive endoderm production |
| CA2954431C (en) * | 2007-11-27 | 2021-08-24 | Lifescan, Inc. | Differentiation of human embryonic stem cells to pancreatic cells |
| EP2227487A1 (en) | 2007-12-28 | 2010-09-15 | Novo Nordisk A/S | Ddr1-mediated cell purification of pancreatic endocrine cells through their progenitors |
| RU2551772C2 (ru) | 2008-02-21 | 2015-05-27 | Сентокор Орто Байотек Инк. | Способы, поверхностно-модифицированные носители и композиции для иммобилизации, культивирования и открепления клеток |
| JP2011518547A (ja) | 2008-04-03 | 2011-06-30 | ノボ・ノルデイスク・エー／エス | 膵臓内分泌プレ前駆体細胞及びその子孫のｄｎｅｒ媒介細胞精製 |
| US8623648B2 (en) | 2008-04-24 | 2014-01-07 | Janssen Biotech, Inc. | Treatment of pluripotent cells |
| US7939322B2 (en) | 2008-04-24 | 2011-05-10 | Centocor Ortho Biotech Inc. | Cells expressing pluripotency markers and expressing markers characteristic of the definitive endoderm |
| AU2009267137A1 (en) | 2008-06-30 | 2010-01-07 | Centocor Ortho Biotech Inc. | Differentiation of pluripotent stem cells |
| MX2011000123A (es) * | 2008-06-30 | 2011-02-25 | Centocor Ortho Biotech Inc | Diferenciacion de las celulas madre pluripotentes. |
| MX2011004565A (es) | 2008-10-31 | 2011-07-28 | Centocor Ortho Biotech Inc | Diferenciacion de celulas madre embrionarias humanas al linaje endocrino pancreatico. |
| MX2011004563A (es) | 2008-10-31 | 2011-06-01 | Centocor Ortho Biotech Inc | Diferenciacion de celulas madre embrionarias humanas al linaje endocrino pancreatico. |
| US8008075B2 (en) | 2008-11-04 | 2011-08-30 | Viacyte, Inc. | Stem cell aggregate suspension compositions and methods of differentiation thereof |
| US8895300B2 (en) | 2008-11-04 | 2014-11-25 | Viacyte, Inc. | Scalable primate pluripotent stem cell aggregate suspension culture and differentiation thereof |
| EP3363444B1 (en) | 2008-11-14 | 2022-09-14 | ViaCyte, Inc. | Encapsulation of pancreatic cells derived from human pluripotent stem cells |
| EP3260534A1 (en) | 2008-11-20 | 2017-12-27 | Janssen Biotech, Inc. | Pluripotent stem cell culture on micro-carriers |
| BRPI0921996A2 (pt) | 2008-11-20 | 2015-08-18 | Centocor Ortho Biotech Inc | Métodos e composições para cultura e ligação de células em substratos planos. |
| KR101785626B1 (ko) | 2009-07-20 | 2017-10-16 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 분화 |
| EP2456862A4 (en) | 2009-07-20 | 2013-02-27 | Janssen Biotech Inc | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS |
| KR101786735B1 (ko) | 2009-07-20 | 2017-10-18 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 분화 |
| BR112012017761A2 (pt) | 2009-12-23 | 2015-09-15 | Centocor Ortho Biotech Inc | diferenciação das células-tronco embrionárias humanas |
| US12441985B2 (en) | 2009-12-23 | 2025-10-14 | Janssen Biotech, Inc. | Methods for making insulin in vivo |
| PH12012501254A1 (en) | 2009-12-23 | 2012-11-05 | Janssen Biotech Inc | Differentiation of human embryonic stem cells |
| US9969981B2 (en) | 2010-03-01 | 2018-05-15 | Janssen Biotech, Inc. | Methods for purifying cells derived from pluripotent stem cells |
| US9719068B2 (en) | 2010-05-06 | 2017-08-01 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| RU2663339C1 (ru) | 2010-05-12 | 2018-08-03 | Янссен Байотек, Инк. | Дифференцирование эмбриональных стволовых клеток человека |
| KR101836850B1 (ko) | 2010-08-31 | 2018-03-09 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 분화 |
| CA2809300A1 (en) | 2010-08-31 | 2012-03-08 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
| JP6133776B2 (ja) | 2010-08-31 | 2017-05-24 | ヤンセン バイオテツク，インコーポレーテツド | 多能性幹細胞の分化 |
| JP5888852B2 (ja) * | 2010-12-08 | 2016-03-22 | 学校法人近畿大学 | 免疫不全動物を用いた細胞の製法 |
| JP2012143229A (ja) * | 2010-12-24 | 2012-08-02 | Chiba Univ | 多能性幹細胞培養用組成物およびその用途 |
| ES2902650T3 (es) | 2011-06-21 | 2022-03-29 | Novo Nordisk As | Inducción eficiente de endodermo definitivo a partir de células madre pluripotentes |
| RU2018128383A (ru) | 2012-03-07 | 2019-03-14 | Янссен Байотек, Инк. | Среда определенного состава для размножения и обновления плюрипотентных стволовых клеток |
| RU2018108850A (ru) | 2012-06-08 | 2019-02-26 | Янссен Байотек, Инк. | Дифференцировка эмбриональных стволовых клеток человека в панкреатические эндокринные клетки |
| US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
| SG10201707811XA (en) | 2012-12-31 | 2017-11-29 | Janssen Biotech Inc | Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators |
| MX2015008577A (es) | 2012-12-31 | 2015-09-07 | Janssen Biotech Inc | Cultivo de celulas madre embrionarias humanas en la interfase aire-liquido para la diferenciacion en celulas endocrinas pancreaticas. |
| EP4039798A1 (en) | 2012-12-31 | 2022-08-10 | Janssen Biotech, Inc. | Suspension and clustering of human pluripotent cells |
| KR102162138B1 (ko) | 2014-05-16 | 2020-10-06 | 얀센 바이오테크 인코포레이티드 | 췌장 내분비 세포에서 mafa 발현을 향상시키기 위한 소분자의 용도 |
| EP3149156B1 (en) * | 2014-05-28 | 2021-02-17 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
| JP6804438B2 (ja) | 2014-10-17 | 2020-12-23 | チルドレンズ ホスピタル メディカル センター | 多能性幹細胞を使用するヒト小腸のｉｎ ｖｉｖｏモデル、並びにそれを作製、及び使用する方法 |
| US10494608B2 (en) | 2015-04-24 | 2019-12-03 | University Of Copenhagen | Isolation of bona fide pancreatic progenitor cells |
| MA45479A (fr) | 2016-04-14 | 2019-02-20 | Janssen Biotech Inc | Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen |
| EP4177335A1 (en) | 2016-05-05 | 2023-05-10 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
| EP3534976A4 (en) | 2016-11-04 | 2020-09-16 | Children's Hospital Medical Center | PATHOLOGICAL MODELS OF HEPATIC ORGANOIDS AND ASSOCIATED METHODS OF MANUFACTURE AND USE |
| EP3548507A4 (en) | 2016-12-05 | 2020-07-15 | Children's Hospital Medical Center | COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF |
| EP3609997A4 (en) | 2017-04-14 | 2021-03-03 | Children's Hospital Medical Center | COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES |
| EP3694603A4 (en) | 2017-10-10 | 2021-07-14 | Children's Hospital Medical Center | ESOPHAGUS TISSUE AND / OR ORGANOID COMPOSITIONS AND METHOD FOR MANUFACTURING THEREOF |
| CA2983845C (en) | 2017-10-26 | 2024-01-30 | University Of Copenhagen | Generation of glucose-responsive beta cells |
| US12379372B2 (en) | 2017-12-21 | 2025-08-05 | Children's Hospital Medical Center | Digitalized human organoids and methods of using same |
| KR102887406B1 (ko) | 2018-07-26 | 2025-11-19 | 칠드런즈 호스피탈 메디칼 센터 | 간-담도-췌장 조직 및 이를 제조하는 방법 |
| WO2020056158A1 (en) | 2018-09-12 | 2020-03-19 | Children's Hospital Medical Center | Organoid compositions for the production of hematopoietic stem cells and derivatives thereof |
| AU2020283056B2 (en) | 2019-05-31 | 2023-06-08 | Viacyte, Inc. | A biocompatible membrane composite |
| EP3976237A1 (en) | 2019-05-31 | 2022-04-06 | W.L. Gore & Associates Inc. | Cell encapsulation devices with controlled oxygen diffusion distances |
| EP3975926A1 (en) | 2019-05-31 | 2022-04-06 | W.L. Gore & Associates, Inc. | A biocompatible membrane composite |
| CA3139591C (en) | 2019-05-31 | 2024-01-16 | Timothy M. BRUHN | A biocompatible membrane composite |
| CA3190604A1 (en) | 2020-08-15 | 2022-02-24 | Regeneron Pharmaceuticals, Inc. | Treatment of obesity in subjects having variant nucleic acid molecules encoding calcitonin receptor (calcr) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1298201A1 (en) * | 2001-09-27 | 2003-04-02 | Cardion AG | Process for the production of cells exhibiting an islet-beta-cell-like state |
| US20030138949A1 (en) * | 2001-12-12 | 2003-07-24 | Anil Bhushan | Methods for the regeneration of pancreatic islets and expansion of pancreatic endocrine cells |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3945846B2 (ja) * | 1995-11-09 | 2007-07-18 | 武田薬品工業株式会社 | 膵臓機能改善剤 |
| US6331406B1 (en) * | 1997-03-31 | 2001-12-18 | The John Hopkins University School Of Medicine | Human enbryonic germ cell and methods of use |
| EP1175487A2 (en) * | 1999-02-10 | 2002-01-30 | Curis, Inc. | Pancreatic progenitor cells, methods and uses related thereto |
| JP4426064B2 (ja) * | 2000-05-31 | 2010-03-03 | 独立行政法人科学技術振興機構 | 脊椎動物の膵臓のインビトロ形成方法 |
| WO2002002750A1 (en) * | 2000-06-30 | 2002-01-10 | Amcyte, Inc. | Culturing pancreatic stem cells having a specified, intermediate stage of development |
| AU8617301A (en) * | 2000-08-01 | 2002-02-13 | Yissum Res Dev Co | Directed differentiation of embryonic cells |
| US20020168763A1 (en) * | 2000-11-30 | 2002-11-14 | Yan Wen Liang | Isolated homozygous stem cells, differentiated cells derived therefrom, and materials and methods for making and using same |
| EP1366148A2 (en) * | 2001-01-24 | 2003-12-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES | Differentiation of stem cells to pancreatic endocrine cells |
| EP1393066A4 (en) * | 2001-05-15 | 2006-01-25 | Rappaport Family Inst For Res | INSULIN-PRODUCING CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS |
| CA2451838A1 (en) * | 2001-05-25 | 2002-12-05 | Cythera, Inc. | Stem cell differentiation |
| WO2002102982A2 (en) * | 2001-06-14 | 2002-12-27 | Regents Of The University Of California | Hoxd3 compositions ad methods for improved wound healing |
| WO2003046141A2 (en) * | 2001-11-26 | 2003-06-05 | Advanced Cell Technology, Inc. | Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells |
| GB2399823B (en) * | 2001-12-07 | 2006-02-15 | Geron Corp | Islet cells from primate pluripotent stem cells |
| US20030162290A1 (en) * | 2002-01-25 | 2003-08-28 | Kazutomo Inoue | Method for inducing differentiation of embryonic stem cells into functioning cells |
| WO2003089619A2 (en) * | 2002-04-19 | 2003-10-30 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Placental derived stem cells and uses thereof |
| EP1516925A1 (en) * | 2003-09-18 | 2005-03-23 | Fundacion IVI para el Estudio de la reproduccion Humana (FIVIER) | Generation of human embryonic stem cells from triploid zygotes |
| CA2555571C (en) * | 2004-04-01 | 2012-10-16 | Wisconsin Alumni Research Foundation | Differentiation of stem cells to endoderm and pancreatic lineage |
-
2005
- 2005-04-26 ES ES05780039T patent/ES2751095T3/es not_active Expired - Lifetime
- 2005-04-26 CN CN201210431212.6A patent/CN103103158B/zh not_active Expired - Lifetime
- 2005-04-26 WO PCT/US2005/014239 patent/WO2005116073A2/en not_active Ceased
- 2005-04-26 SG SG200902871-3A patent/SG152273A1/en unknown
- 2005-04-26 KR KR1020107004283A patent/KR101395516B1/ko not_active Expired - Lifetime
- 2005-04-26 CA CA2564114A patent/CA2564114C/en not_active Expired - Lifetime
- 2005-04-26 JP JP2007510879A patent/JP4926946B2/ja not_active Expired - Lifetime
- 2005-04-26 AU AU2005247869A patent/AU2005247869B2/en not_active Expired
- 2005-04-26 EA EA200601995A patent/EA011953B1/ru not_active IP Right Cessation
- 2005-04-26 DK DK10012385.0T patent/DK2377922T3/da active
- 2005-04-26 DK DK05780039.3T patent/DK1740612T3/da active
- 2005-04-26 KR KR1020067022588A patent/KR101278421B1/ko not_active Expired - Lifetime
- 2005-04-26 ES ES10012385T patent/ES2801001T3/es not_active Expired - Lifetime
- 2005-04-26 EP EP05780039.3A patent/EP1740612B1/en not_active Expired - Lifetime
- 2005-04-26 NZ NZ550605A patent/NZ550605A/en not_active IP Right Cessation
- 2005-04-26 MX MXPA06012445A patent/MXPA06012445A/es active IP Right Grant
-
2006
- 2006-10-24 IL IL178847A patent/IL178847A/en active IP Right Grant
-
2011
- 2011-07-01 JP JP2011147598A patent/JP5669681B2/ja not_active Expired - Lifetime
-
2014
- 2014-08-22 JP JP2014168939A patent/JP6158152B2/ja not_active Expired - Lifetime
-
2015
- 2015-06-01 JP JP2015111656A patent/JP6265942B2/ja not_active Expired - Lifetime
-
2017
- 2017-02-16 JP JP2017026645A patent/JP6605520B2/ja not_active Expired - Lifetime
-
2018
- 2018-09-06 JP JP2018167312A patent/JP6709262B2/ja not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1298201A1 (en) * | 2001-09-27 | 2003-04-02 | Cardion AG | Process for the production of cells exhibiting an islet-beta-cell-like state |
| US20030138949A1 (en) * | 2001-12-12 | 2003-07-24 | Anil Bhushan | Methods for the regeneration of pancreatic islets and expansion of pancreatic endocrine cells |
Non-Patent Citations (4)
| Title |
|---|
| KAHAN BRENDA W. ET AL.: "Pancreatic precursors and differentiated islet cell types from murine embryonic stem cells: An in vitro model to study islet differentiation", DIABETES, vol. 52, no. 8, August 2003 (2003-08), pages 2016-2024, XP002365297, ISSN: 0012-1797, abstract, page 2016, column 2, paragraph 2, page 2017, column 1, paragraphs 2, 3, page 2018, column 2, last paragraph - page 2019, column 1, paragraph 2 * |
| KANAI-AZUMA MASAMI ET AL.: "Depletion of definitive gut endoderm in Sox17-null mutant mice", DEVELOPMENT (CAMBRIDGE), vol. 129, no. 10, May 2002 (2002-05), pages 2367-2379, XP002350818, ISSN: 0950-1991, abstract * |
| MICALLEF SUZANNE J. ET AL.: "Retinoic acid induces Pdx1-positive endoderm in differentiating mouse embryonic stem cells", DIABETES, vol. 54, no. 2, February 2005 (2005-02), pages 301-305, XP002364807, ISSN: 0012-1797, the whole document * |
| SKOUDY ANOUCHKA ET AL.: "Transforming growth factor (TGF)beta, fibroblast growth factor (FGF) and retinoid signalling pathways promote pancreatic exocrine gene expression in mouse embryonic stem cells", THE BIOCHEMICAL JOURNAL. 1 MAY 2004, vol. 379, no. Pt 3, 1 May 2004 (2004-05-01), pages 749-756, XP002365298, ISSN: 1470-8728, the whole document * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2668798C2 (ru) * | 2011-12-22 | 2018-10-02 | Янссен Байотек, Инк. | Способы in vitro пошаговой дифференцировки полюрипотентных клеток |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA011953B1 (ru) | Pdx1-экспрессирующая энтодерма | |
| Albano et al. | Activins are expressed in preimplantation mouse embryos and in ES and EC cells and are regulated on their differentiation | |
| Darlington | Molecular mechanisms of liver development and differentiation | |
| Viebahn | Epithelio-mesenchymal transformation during formation of the mesoderm in the mammalian embryo | |
| Myer et al. | MyoD cannot compensate for the absence of myogenin during skeletal muscle differentiation in murine embryonic stem cells | |
| US20030219866A1 (en) | Stem cell-like cells | |
| US20150368616A1 (en) | Methods for induction of cell fates from pluripotent cells | |
| AU2014236150A1 (en) | In vitro production of medial ganglionic eminence precursor cells | |
| JP2004511209A (ja) | 細胞の脱分化及び組織の再生のための組成物及び方法 | |
| JP2010517578A (ja) | Ｉｓｌｅｔ１＋系統に入るように細胞を誘導する方法およびそれを拡大する方法 | |
| US20160194608A1 (en) | Methods for Inducing Cardiomyogenesis | |
| JP7302865B2 (ja) | 未成熟卵母細胞の誘導方法及び成熟卵母細胞の作製方法 | |
| Tiedemann et al. | Pluripotent cells (stem cells) and their determination and differentiation in early vertebrate embryogenesis | |
| TW202200786A (zh) | 自肺上皮細胞或肺癌細胞製造類器官之方法 | |
| JP5174019B2 (ja) | Ｇ−ｃｓｆを用いた心筋細胞への分化誘導方法 | |
| Nishinakamura et al. | Essential roles of Sall family genes in kidney development | |
| KR20070030164A (ko) | Ｅｓ 세포 자가 재생 및 계통 지정의 조절, 및 이를 위한배지 | |
| US20220155314A1 (en) | Trophoblast stem cell, methods of preparation and uses thereof | |
| Fukui et al. | Control of cell differentiation and morphogenesis in amphibian development. | |
| KR101312048B1 (ko) | 줄기세포의 혈관계 또는 근육계 세포로의 분화유도 방법 | |
| US20130004984A1 (en) | Neuronal stimulation | |
| WO2008051949A2 (en) | Gpr125 as a marker for stem and progenitor cells and methods use thereof | |
| US20020132239A1 (en) | Cell lineage markers | |
| Rong et al. | The impact of dynamic caudal type homeobox 2 expression on the differentiation of human trophoblast lineage during implantation | |
| WO2017223340A1 (en) | Enhanced hematopoietic stem cell transplantation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD4A | Registration of transfer of a eurasian patent in accordance with the succession in title | ||
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |